SCHEMBL13019103

SCHEMBL13019103

Cc1c(-c2ccccn2)nc2cc(F)cc(F)c2c1Nc1cccc(Br)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.49
PIK3CA P42336 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 3/20 0.39
GAA P10253 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.39
KDR P35968 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
EGFR P00533 4/20 0.36
ABL1 P00519 1/20 0.35
ABL2 P42684 1/20 0.35
TNF P01375 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP1B1 Q16678 1/20 0.35
ABCB1 P08183 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2713418 0.88 PIK3CD (0.50) PIK3CDPIK3CAKDM4ENPC1TP53
SCHEMBL2714914 0.79 KDM4E (0.49) PIK3CDPIK3CAKDM4ENPC1
SCHEMBL242698 0.78 PIK3CD (0.49) PIK3CDPIK3CAKDM4ENPC1TP53
SCHEMBL2713259 0.77 PIK3CD (0.54) PIK3CDPIK3CANPC1GAASMN1; SMN2
SCHEMBL2713525 0.77 PIK3CD (0.41) PIK3CDPIK3CANPC1
SCHEMBL2712834 0.76 PIK3CD (0.52) PIK3CDPIK3CAKDM4ENPC1TP53
SCHEMBL2710923 0.76 PIK3CD (0.59) PIK3CDPIK3CAKDM4ENPC1SMN1; SMN2
SCHEMBL2712617 0.76 PIK3CD (0.55) PIK3CDPIK3CA
SCHEMBL2711317 0.75 PIK3CD (0.55) PIK3CDPIK3CAKDM4ENPC1
SCHEMBL2711701 0.75 PIK3CD (0.56) PIK3CDPIK3CAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 14/4885PIK3CA 29/4885KDM4E 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.